Coronavirus Update: Moderna Ready For Interim Analysis, Brazil Resumes SinoVac Trial
Plus a plant-derived COVID-19 vaccine moves into Phase II/III
Executive Summary
Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.
You may also be interested in...
Deal Watch: Artios Links Up With Novartis On DNA Damage Response Modifiers
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Coronavirus Notebook: Pfizer/BioNTech & Russian Vaccines Each Claim Efficacy Of More than 90%
As data start to come in on the first coronavirus vaccines, hopes are rising that vaccination campaigns will be able to begin in the next month or two, although experts have cautioned against unbridled optimism. Uncertainties also remain over questions such as whom to vaccinate first and how to assure equitable access in less wealthy parts of the world.
The World Celebrates Pfizer's 90% COVID-19 Vaccine Efficacy Data, With Cautious Caveats
Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.